Managers / Q2 2021 · view latest →
Corriente Advisors, LLC
CIK 0001406718 · 1401 FOCH ST, SUITE 100, FORT WORTH, TX, 76107 · 8178700400
Summary
Corriente Advisors, LLC reported $185M in U.S.-listed holdings across 15 positions for Q2 2021.
The portfolio is heavily concentrated: Maxar Technologies alone accounts for 41.3% of reported value.
Compared with Q1 2021, the fund opened 9 new positions and exited 4.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 98.2% · $182M
- ADR · 1.8% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| COINCOINBASE GLOBAL INC | NEW | +40.0K | 40.0K | +$10M | $10M |
| REATA PHARMACEUTICALS INC | NEW | +71.1K | 71.1K | +$10M | $10M |
| QSQUANTUMSCAPE CORP | NEW | +337.3K | 337.3K | +$10M | $10M |
| KTOSKRATOS DEFENSE & SEC SOLUTIO | NEW | +275.7K | 275.7K | +$8M | $8M |
| MPMP MATERIALS CORP | NEW | +110.0K | 110.0K | +$4M | $4M |
| HIMXHIMAX TECHNOLOGIES INC | NEW | +200.0K | 200.0K | +$3M | $3M |
| CRSPCRISPR THERAPEUTICS AG | NEW | +20.0K | 20.0K | +$3M | $3M |
| IRDMIRIDIUM COMMUNICATIONS INC | NEW | +80.0K | 80.0K | +$3M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MAXAR TECHNOLOGIES INC | COM | 41.35% | $77M | 1.92M |
| 2 | CUE BIOPHARMA INC | COM | 9.34% | $17M | 1.49M |
| 3 | REPLREPLIMUNE GROUP INChistory → | COM | 9.32% | $17M | 449.9K |
| 4 | COINCOINBASE GLOBAL INChistory → | COM CL A | 5.46% | $10M | 40.0K |
| 5 | REATA PHARMACEUTICALS INC | CL A | 5.43% | $10M | 71.1K |
| 6 | QSQUANTUMSCAPE CORPhistory → | COM CL A | 5.32% | $10M | 337.3K |
| 7 | LTRNLANTERN PHARMA INChistory → | COM | 5.17% | $10M | 656.4K |
| 8 | CRDFCARDIFF ONCOLOGY INChistory → | COM | 4.96% | $9M | 1.38M |
| 9 | KTOSKRATOS DEFENSE & SEC SOLUTIOhistory → | COM NEW | 4.24% | $8M | 275.7K |
| 10 | MPMP MATERIALS CORPhistory → | COM CL A | 2.19% | $4M | 110.0K |
| 11 | HIMXHIMAX TECHNOLOGIES INChistory → | SPONSORED ADR | 1.80% | $3M | 200.0K |
| 12 | CRSPCRISPR THERAPEUTICS AGhistory → | NAMEN AKT | 1.75% | $3M | 20.0K |
| 13 | IRDMIRIDIUM COMMUNICATIONS INChistory → | COM | 1.73% | $3M | 80.0K |
| 14 | RBLXROBLOX CORPhistory → | CL A | 1.46% | $3M | 30.0K |
| 15 | DMACDIAMEDICA THERAPEUTICS INC | COM NEW | 0.49% | $906,000 | 203.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $10M | 3 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | Under review | 7 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $10,872 | 2 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $976,400 | 2 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $0 | 1 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $90M | 5 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $237M | 5 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $268M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $12M | 3 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $52M | 8 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $185M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $272M | 10 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $420M | 19 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $197M | 16 | Nov 3, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $154M | 16 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 11 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $186M | 17 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.